1177 — Sino Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$98.09bn
- HK$101.92bn
- CNY31.83bn
Brief: Sino Biopharmaceutical Says Her2-Selective TKI Granted Breakthrough Therapeutic Designation
Brief: Sino Biopharmaceutical LM-302 Included In Breakthrough Therapeutic Designation Process By China's NMPA
Brief: Sino Biopharmaceutical Declares Interim Dividend Of HK5 Cents Per Share
Brief: Sino Biopharmaceutical Says China's NMPA Accepts Clinical Trial Application For TQB3142 "BCL-XL Protac"
Brief: Sino Biopharmaceutical Says Application For Clinical Trial Of TQB3122 Accepted By NMPA
Brief: Sino Biopharmaceutical Says Application For Phase II Clinical Trial On LM-24C5 "CEACAM5/4-1BB Bispecific Antibody" Approved By China NMPA
Brief: Sino Biopharmaceutical's Rovadicitinib Tablet Included In Breakthrough Therapeutic Designation
Brief: Sino Biopharmaceutical Says NMPA Approves Clinical Trial For Sino Biopharm's TQC3302
Sino Biopharmaceutical hits almost 4-year peak on plan to buy out LaNova
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Brief: Sino Biopharmaceutical Fully Buys Lanova Medicines
Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million (updated)
Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million
Brief: Sino Biopharmaceutical Updates On Culmerciclib Capsule
Brief: Sino Biopharmaceutical Says Recombinant Human Coagulation Factor Viia N01 Approved By NMPA
Brief: Sino Biopharmaceutical Says LM-108 Included In Breakthrough Therapy Designation
Brief: Sino Biopharmaceutical Says New Indication Of TDI01 Suspension ("Rock2 Inhibitor") Included In Breakthrough Therapy Designation Process By CDE
Brief: Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection